Improving cardiotoxicity prediction in cancer treatment: integration of conventional circulating biomarkers and novel exploratory tools
| Autor: | Feng Wei, Li Pang, Chengzhong Cai, Xi Yang, Zhichao Liu |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty Health Toxicology and Mutagenesis Antineoplastic Agents Disease 010501 environmental sciences Toxicology 01 natural sciences 03 medical and health sciences Artificial Intelligence Neoplasms Animals Humans Medicine Precision Medicine Intensive care medicine 0105 earth and related environmental sciences Genetic testing Cardiotoxicity medicine.diagnostic_test business.industry Reproducibility of Results Cancer General Medicine Precision medicine Omics medicine.disease Clinical trial 030104 developmental biology Biomarker (medicine) business Biomarkers |
| Zdroj: | Archives of Toxicology. 95:791-805 |
| ISSN: | 1432-0738 0340-5761 |
| Popis: | Early detection strategies and improvements in cancer treatment have dramatically reduced the cancer mortality rate in the United States (US). However, cardiovascular (CV) side effects of cancer therapy are frequent among the 17 million cancer survivors in the US today, and cardiovascular disease (CVD) has become the second leading cause of morbidity and mortality among cancer survivors. Circulating biomarkers are ideal for detecting and monitoring CV side effects of cancer therapy. Here, we summarize the current state of clinical studies on conventional serum and plasma CVD biomarkers to detect and prevent cardiac injury during cancer treatment. We also review how novel exploratory tools such as genetic testing, human stem cell-derived cardiomyocytes, Omics technologies, and artificial intelligence can elucidate underlying molecular and genetic mechanisms of CV injury and to improve predicting cancer therapy-related cardiotoxicity (CTRC). Current regulatory requirements for biomarker qualifications are also addressed. We present generally applicable lessons learned from published studies, particularly on how to improve reproducibility. The combination of conventional circulating biomarkers and novel exploratory tools will pave the way for precision medicine and improve the clinical practice of prediction, detection, and management of CTRC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink